Novartis Seeks To Fracture Class In Bone Drug Suit
Locked in a battle over bone cancer drugs Aredia and Zometa, Novartis Pharmaceutical Corp. has asked the district judge overseeing the multidistrict product liability litigation to break apart a current class...To view the full article, register now.
Already a subscriber? Click here to view full article